Song Xiaohong, Chen Zhaoran, Zheng Yuehong, Wu Jianqiang
Department of Vascular Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Geriatrics, Medical Health Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Expert Rev Proteomics. 2024 Dec 3:1-15. doi: 10.1080/14789450.2024.2436401.
Cardiovascular diseases (CVDs) are the leading causes of mortality and morbidity worldwide, making early diagnosis and effective treatment essential. As a promising and noninvasive research method, urine proteomics shows excellent potential to identify reliable urinary biomarkers that could enhance prediction, prevention, and prognosis in patients with CVD.
This review summarizes recent advancements in urinary protein biomarker profiling using urine proteomic techniques to identify potential CVD biomarkers. Additionally, it highlights potential disease biomarkers for the early detection, risk stratification, and monitoring of CVD, including hypertension, atherosclerosis, coronary artery disease, angina, myocardial infarction, heart failure, preeclampsia, and vasculitis. A literature search was conducted through Pubmed, Scopus, Google Scholar, and Web of Science. The period is January 2009 to February 2024.
Over the past decade, urinary proteomics has been employed in CVD research, with the potential to facilitate the discovery of novel disease biomarkers and the exploration of prospective therapeutic targets. Proteomics-based multicenter cohort studies should be conducted in the future to gain deeper insights into the pathophysiological mechanisms of CVD, accelerate the identification of potential biomarkers for disease prediction, diagnosis, and treatment, and facilitate their clinical translation.
心血管疾病（CVD）是全球死亡和发病的主要原因，因此早期诊断和有效治疗至关重要。作为一种有前景的非侵入性研究方法，尿液蛋白质组学在识别可靠的尿液生物标志物方面显示出巨大潜力，这些生物标志物可以增强对CVD患者的预测、预防和预后评估。
本综述总结了使用尿液蛋白质组学技术进行尿液蛋白质生物标志物分析以识别潜在CVD生物标志物的最新进展。此外，还强调了用于早期检测、风险分层和监测CVD的潜在疾病生物标志物，包括高血压、动脉粥样硬化、冠状动脉疾病、心绞痛、心肌梗死、心力衰竭、先兆子痫和血管炎。通过PubMed、Scopus、谷歌学术和科学网进行了文献检索。检索时间段为2009年1月至2024年2月。
在过去十年中，尿液蛋白质组学已应用于CVD研究，有潜力促进新型疾病生物标志物的发现以及前瞻性治疗靶点的探索。未来应开展基于蛋白质组学的多中心队列研究，以更深入地了解CVD的病理生理机制，加速识别用于疾病预测、诊断和治疗的潜在生物标志物，并促进其临床转化。
